Precipio Posts Record $7.3M Quarterly Revenue, Turns GAAP Profitable
PRPO sits 33% above its 52-week low of $17.79 on light trading volume (0.2× avg).
Summary
Precipio delivered record quarterly revenue of $7.3M, up 8% from $6.8M a year ago and above the $7.0M posted in Q2. Product revenue jumped 40% year-over-year to $1.0M while pathology revenue grew 5% to $6.3M. The company swung to roughly breakeven on a GAAP basis, with net income of $0.0M versus a $(0.1)M loss in Q3-2025, and generated $0.6M of operating cash flow, lifting cash to more than $3.5M from $2.3M a year earlier. Adjusted EBITDA slipped to $0.4M from $0.5M, so the profitability improvement is thin and the prior going-concern warning from the Q2 10-Q remains the key overhang for a company this small. The 10-Q filed today carries the full detail; management discusses results on the 5 PM ET shareholder call.
At the time of this announcement, PRPO was trading at $23.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.3M. The 52-week trading range was $17.79 to $33.63. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.